Mack Roach

Mack Roach MD

Mack Roach III, M.D., F.A.C.R.

Departments of Radiation Oncology & Urology

University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
Box 1708, 1600 Divisadero St, H1031
San Francisco, CA 94115
Phone: (415) 353-9860
Fax: (415) 353-9883
Email: mack.roach[at]

Make A Gift Button

Professional Focus

Dr. Roach is a Professor of Radiation Oncology and Urology in the Department of Radiation Oncology at the University of California San Francisco. He is recognized as a major authority on the treatment of localized prostate cancer. His research interests involve the application of image-guided intensity-modulated radiation therapy (IMRT) and Brachytherapy and defining the optimal imaging modalities and criteria for selecting specific targets for radiation, while minimizing treatment related complications. He has helped to pioneer the use of endorectal Magnetic Spectroscopy imaging as a means of monitoring prostate cancer outcomes. Dr. Roach was a leader in establishing the American College of Radiology (ACR) Appropriateness Criteria Guidelines for defining how men with prostate cancer should be treated with radiotherapy from 1996 through 2006. He also served on the NCI Intensity Modulated Radiotherapy Working Group describing criteria for the use of this new technology and currently serves on the National Comprehensive Cancer Guidelines Committee for Prostate Cancer. He has been the recipient of numerous awards, such as the American Cancer Society Career Development Award and the UCSF Health Net Wellness Award. He is a Fellow of the ACR and ASTRO. Dr. Roach has co-authored more than 400 peer-reviewed journal articles, book chapters and/or editorials. He has served on numerous editorial boards and was appointed (2013) by President Obama to serve a 6-year term on the National Cancer Advisory Board (NCAB) which is involved in defining the research agenda for our nation. He has lead two large Phase III Trials evaluating the role of whole-pelvic radiation in men with high risk prostate cancer, and when completed in total, nearly 4000 men will have been enrolled on these two studies. A major research interest of his work has been to reduce the risk of erectile dysfunction (and other side-effects) associated with treatment of prostate cancer with radiation. He is currently also very active in the efforts to develop the capacity to harness heavy charged particles for the treatment of radiation resistant cancers..


1975 Morehouse College, Atlanta, GA BS (Honors) Physics
1979 Stanford University School of Medicine MD  
1979-1981 Martin Luther King, Jr., General Hospital, Los Angeles, CA Internship and Resident  
1981-1983 UCSF Fellow Hematology-Oncology
1983-1984 Highland General Hospital, Oakland, CA Chief Resident Medicine
1984-1987 Stanford University School of Medicine Resident Radiation Therapy (Chief Resident - 1986)

Professional Experience

2014-present UCSF Professor Radiation Oncology
2007-2014 UCSF Professor & Chair Radiation Oncology
2006-2007 UCSF Professor & Interim Chair Radiation Oncology
2003-2006 UCSF Professor & Vice Chair Radiation Oncology
2003-present UCSF Professor Urology
2001-present UCSF Director, Clinical Research Radiation Oncology
2000-2003 UCSF Professor in Residence Radiation Oncology & Urology
1997-2000 UCSF Associate Professor Urology
1994-2000 UCSF Associate Professor in Residence Radiation Oncology & Medical Oncology
1990-1994 UCSF Assistant Professor in Residence Radiation Oncology
1988-1990 Veterans Administration Medical Center, Martinez, CA Chief Radiation Oncology
1987-1988 Veterans Administration Medical Center, Martinez, CA Acting Chief Radiation Oncology Services

Awards & Honors

1979-1980 Outstanding Intern of the Year (Charles R. Drew Award)
1981-1982 Fellow, American Cancer Society
1994-1997 American Cancer Society, Career Development Award
1994 UCSF Health Net Wellness Award
1996-1997 Best Doctors in America ®
1997, 1998 Best Doctors in the Bay Area
1999 Health & Wellness Award - 100 Black Men of the Bay Area Inc.
2001-2002 Best Doctors in America ®
2002 Fellow, American College of Radiology
2002-2003 President, John Hale Medical Society
2003-2004 Best Doctors in America ®
2005 10 Most Influential African Americans in the Bay Area (Healthcare)
2005-2006 Best Doctors in America ®
2007 UCSF Award for Community Service

The Best Doctors in America ®

2008 Bennie (Mays) Service Award, Morehouse College
2010 American Society for Clinical Oncology, Statesman Award
2012 Presidential Appointment to the National Cancer Advisory Board of the NIH
2014 Fellow, American Society of Radiation Oncology (FASTRO)
2018 National Cancer Institute, Directors Service Award (National Cancer Advisory Board)


Recent Significant Publications :

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. Lancet Oncol. 2018.

Kaidar-Person O, Roach M 3rd, Créhange G. Whole-Pelvic Nodal Radiation Therapy in the Context of Hypofractionation for High-Risk Prostate Cancer Patients: A Step Forward. Int J Radiat Oncol Biol Phys. 2013 Mar 19.

Chang AJ, Roach M 3rd. Cautious Optimism for Extreme Dose Escalation in Prostate Cancer. Eur Urol. 2013 Feb 28.

Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C.Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. Cancer. 2013 Mar 15.

Chen CP, Weinberg V, Shinohara K, Roach M 3rd, Nash M, Gottschalk A, Chang AJ, Hsu IC.Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes.Int J Radiat Oncol Biol Phys. 2013 Mar 5.

Roach M 3rd, Thomas K.Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012 Dec;2012(45):221-9.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd.Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev. 2012 Dec;38(8):956-67.

Roach M 3rd. Long-term potency preservation following brachytherapy for prostate cancer. BJU Int. 2012 Jul;110(2):225.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd. Feasibility of MR Imaging/MR Spectroscopy-Planned Focal Partial Salvage Permanent Prostate Implant (PPI) for Localized Recurrent After Initial PPI for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2012 Jun 4.

Roach M 3rd, Nam J, Gagliardi G, et al. Radiation dose-volume effects and the penile bulb. Int J Radiat Oncol Biol Phys. 76:S130-134 (2010)

Roach M,Hanks G, Thames Jr .H, Schellhammer P, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4): 965-974, 2006.

Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, et al. Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases. J Natl Cancer Inst. 97(11):1-7, 2005.